Oxford Biodyn Regulatory News (OBD)

Oxford BioDynamics Plc

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

Board Appointment

Oxford, UK - 15 April 2026 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, is pleased to announce the appointment of Martin Diggle as a Non-Executive Director with effect from 15 April 2026.

Martin was nominated by Vulpes Investment Management, the Company's largest shareholder through the Vulpes Testudo fund and the Vulpes Life Sciences fund, replacing Stephen Diggle who stepped down as a Director of the Company on 26 January 2026. Martin is the co-founder of Vulpes Investment Management, and Chairman and director of the Vulpes Life Sciences fund.

Martin has extensive experience in the life sciences sector and has served on the Board of several public and privately listed companies such as Oxford Biomedica, Scancell, Proteome Sciences, Leucid Bio, Chronos Therapeutics and Oxford Endovascular. Prior to Vulpes, he was a Partner and Director of UBS/Brunswick. Before that, he spent 7 years at Morgan Stanley. Martin graduated from the University of Oxford with a Masters in Philosophy, Politics and Economics.

Executive Chairman Iain Ross said: "Martin brings a wealth of capital markets and life sciences expertise to the Board. I am thankful for his and Vulpes' ongoing support towards OBD and look forward to working together." 

-Ends-

For further details please contact:

Notes to Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE (EpiSwitch Prostate Screening test) and EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.